Aryl hydrocarbon receptor (AhR) agonist. Inhibits osteoclast formation by inhibiting the expression of receptor activator of NF-κB receptor ligand (RANKL). Suppresses growth factor and JAK-2 expression in mice.
Product Details
Formula: | C21H16 |
|
MW: | 268.4 |
|
CAS: | 56-49-5 |
|
Purity: | ≥93% (UPLC) |
|
Identity: | Determined by 1H-NMR and MS. |
|
Appearance: | Yellow solid. |
|
Solubility: | Soluble in chloroform or ethyl acetate. |
|
Shipping: | Ambient |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Regulation of drug metabolism by the interplay of inflammatory signaling, steatosis, and xeno-sensing receptors in HepaRG cells: N. Tanner, et al.; Drug Metab. Dispos.
46, 326 (2018),
Abstract;
The azole fungicide tebuconazole affects human CYP1A1 and CYP1A2 expression by an aryl hydrocarbon receptor-dependent pathway: C. Knebel, et al.; Food Chem. Toxicol.
123, 481 (2018),
Abstract;
Aryl hydrocarbon receptor-mediated suppression of GH receptor and Janus kinase 2 expression in mice: M. Nukaya, et al.; FEBS Lett.
558, 96 (2004),
Abstract;
Characteristic expression of aryl hydrocarbon receptor repressor gene in human tissues: organ-specific distribution and variable induction patterns in mononuclear cells: J. Yamamoto, et al.; Life Sci.
74, 1039 (2004),
Abstract;
Inhibition of osteoclast formation by 3-methylcholanthrene, a ligand for arylhydrocarbon receptor: suppression of osteoclast differentiation factor in osteogenic cells: M. Naruse, et al.; Biochem. Pharmacol.
67, 119 (2004),
Abstract;